Company: DVAX
Filing Date: 2025-04-17
Form Type: DEFC14A
Source: 0000930413-25-001273
Chunk: 7

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: DEFC14A
Chunk 7
---
,” “project,”
“potential,” “seek,” “should,” “think,”
“toward,” “will,” “would” and similar expressions, or the negatives thereof, or they may
use future dates. Forward-looking statements made in this document include statements regarding plans, considerations,
expectations and determinations regarding future compensation decisions; the goals and objectives of our ESG strategies and
initiatives; the planned resignation of certain directors; expectations regarding our pipeline of vaccine candidates;
expectations regarding the benefits of the refinancing of our convertible senior notes; expectations regarding delivering
value for our stockholders; and our future growth and long-term performance. Actual results may differ materially from those
set forth in this proxy statement due to the risks and uncertainties inherent in our business, including risks relating to
our ability to commercialize and supply HEPLISAV-B and advancing the programs in our vaccine pipeline, and risks related to
the implementation of our long-term growth objectives, the aspirational nature of our ESG strategies and initiatives, which
are not guarantees or promises that such strategies and initiatives will be realized or will otherwise result in the
anticipated benefits to Dynavax and/or its stakeholders, as well as other risks detailed in the “Risk Factors”
section of our Annual Report on Form 10-K for the financial year ended December 31, 2024, and periodic filings made
thereafter, as well as discussions of potential risks, uncertainties and other important factors in our other filings with
the U.S. Securities and Exchange Commission. These forward-looking statements are made as of the date hereof, are qualified
in their entirety by this cautionary statement and we undertake no obligation to revise or update information herein to
reflect events or circumstances in the future, even if new information becomes available. Information on
Dynavax’s website at www.dynavax.com is not incorporated by reference in our current periodic reports with the
SEC.

<div align='center'>DYNAVAX TECHNOLOGIES CORPORATION

2100 Powell Street, Suite 720
Emeryville, California 94608

PROXY STATEMENT

FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS

To be Held on June 11, 2025

GENERAL INFORMATION AND SUMMARY</div>

This summary highlights certain information related to topics discussed
in this proxy statement. This summary does not contain all of the information you should consider, and you should read this entire proxy
statement carefully before voting. The proxy materials, including this proxy